...
首页> 外文期刊>International journal of clinical practice >Clinical impact of a prospective audit with intervention and feedback without carbapenem restriction in patients receiving carbapenem injection
【24h】

Clinical impact of a prospective audit with intervention and feedback without carbapenem restriction in patients receiving carbapenem injection

机译:前瞻性审计在接受Carbapemem注射患者中没有Carbapenem限制的临床影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Antimicrobial stewardship is required to ensure the appropriate use of antimicrobials. However, few reports have shown the impact of antimicrobial stewardship on clinical outcomes. Methods To evaluate the clinical outcomes of implementing a prospective audit with intervention and feedback without carbapenem pre-authorisation, we conducted a single-centre, prospective cohort study in patients who received carbapenem injection. Subjects were allocated to groups receiving antimicrobial agents before (non-intervention group) or after (intervention group) the implementation of an antimicrobial stewardship programme in the clinical setting. Results The intervention facilitated the rate of choice of effective antimicrobials on day 2 from the onset of infection (from 63.2% to 90.2%; P 0.001). Moreover, the rates of clinical failure-free survival (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.47-0.89; P = 0.008) and re-infection-free survival (HR, 0.35; 95% CI, 0.18-0.68; P = 0.002) were significantly higher in the intervention group than in the non-intervention group. A multivariate Cox proportional hazard analysis indicated that non-implementation of antimicrobial stewardship was a significant risk factor for clinical failure in patients receiving carbapenem injection (HR, 1.56; 95% CI, 1.11-2.19; P = 0.010). Conclusions Our prospective audit with intervention and feedback strategy without carbapenem restriction facilitated the choice of optimal antimicrobials at an early stage of infection and improved clinical outcomes in patients who received carbapenem.
机译:背景技术抗微生物管道是确保适当使用抗微生物的管道。然而,很少有报道表明抗菌管道对临床结果的影响。方法评估在没有CarbapeNem预授权的情况下,在没有Carbapenem预授权的情况下实施前瞻性审计的临床结果,我们在接受CarbapeNem注入的患者中进行了单一中心,前瞻性队列研究。将受试者分配给接受(非干预组)或(干预组)在临床环境中实施抗微生物管道方案的抗菌药物。结果干预促进了感染发作时第2天的有效抗微生物的选择率(从63.2%至90.2%; p <0.001)。此外,无临床失败存活率(危害比[HR],0.65; 95%置信区间[CI],0.47-0.89; P = 0.008)和再感染存活(HR,0.35; 95%CI)。在干预组中,0.18-0.68; p = 0.002)显着高于非干预组。多元COX比例危害分析表明,非实施抗微生物管理是接受Carbapenem注射患者临床失败的重要风险因素(HR,1.56; 95%CI,1.11-2.19; P = 0.010)。结论我们对没有Carbapenem限制的干预和反馈策略的前瞻性审计促进了感染早期阶段的最佳抗微生物的选择,并改善了接受CarbapeNem的患者的临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号